Michael Richman - 21 Jun 2023 Form 4 Insider Report for PIERIS PHARMACEUTICALS, INC. (PVLA)

Reporting relationship: Director
Issuer ticker: PVLA
Reported as of: 21 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2023, 16:45:50 UTC
Prior SEC filing: 01 Mar 2023
Next SEC filing: 01 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Ahmed Mousa, Attorney-in-Fact

Key filing fact

Michael Richman filed Form 4 for PIERIS PHARMACEUTICALS, INC. (PVLA) on 23 Jun 2023.

Key facts

This page summarizes Michael Richman's Form 4 filing for PIERIS PHARMACEUTICALS, INC. (PVLA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2023, 16:45.

Change

Previous filing in this sequence was filed on 01 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PIRS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 21 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $0.2600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date.